Control of allergy with skin based immunomodulation

AD的免疫平衡向Th2优势状态转移，我们已经研究了基于皮肤免疫调节系统的各种治疗方法来纠正Th2转移的免疫系统。除了向皮肤补充外源性免疫调节剂之外，我们已经开发了皮肤特异性显性阴性型突变体IL-4表达转基因小鼠。这只小鼠在半抗原诱导的实验性皮炎的早期阶段减少了炎症。从转基因小鼠移植皮肤的野生型小鼠也降低了皮肤病变中的炎症和Th2细胞因子信号蛋白mRNA表达。从角质形成细胞生产治疗肽的概念是治疗包括过敏性疾病在内的各种全身性疾病的有效治疗策略。

Immunological balance in AD is shifted to Th2 dominant conditions, and we have been investigated various therapeutic method to correct Th2 shifted immune systems based on the skin immunomodulation systems. In addition to supplementation of exogenous immunomodulators to the skin, we have developed a skin specific dominant negative type mutant IL-4 expressing transgenic mouse. This mouse decreased inflammation in a hapteninduced experimental dermatitis at the early phase. Wild type mouse with skin graft from the transgenic mouse, also decreased inflammation and Th2 cytokine signal proteins mRNA expression in the skin lesions. This concept, production of therapeutic peptide from keratinocytes, is a potent therapeutic strategy for various systemic diseases including allergic diseases.